How to Value a Psychiatry Practice in 2026

Psychiatry practices are among the most sought-after acquisitions in healthcare right now, and it's not hard to see why. There's a severe and worsening provider shortage, demand is at all-time highs, reimbursement rates are stable, and telehealth has unlocked geographic flexibility that didn't exist five years ago. Private equity has taken notice — behavioral health platform deals have accelerated dramatically since 2022.

But the valuation dynamics of a psychiatry practice are different from other medical specialties in important ways. I've worked on enough behavioral health transactions to know that the standard "percentage of collections" framework that works for dentistry or primary care breaks down in psychiatry. Here's what actually drives the numbers.

The Valuation Range

Psychiatry practices typically trade at 4-8x EBITDA, a wider range than most medical specialties. The spread reflects the enormous variation in practice models — a solo psychiatrist doing 50/50 therapy and medication management is a fundamentally different business than a multi-provider group with six prescribers running 15-minute med checks all day.

For smaller solo practices, SDE multiples of 2-4x are more common, especially when the selling psychiatrist is irreplaceable (which, in this market, they usually are). Larger groups with $1M+ EBITDA attract institutional buyers — PE-backed behavioral health platforms — and that's where multiples push to 6-8x.

The provider shortage creates what I call a "floor" under psychiatry valuations. Even a mediocre practice with mediocre financials has value because the patients and the provider licenses are scarce resources. I've seen practices with below-average margins still fetch 4-5x EBITDA because a platform buyer needed the prescriber capacity.

Patient Panel Size and Composition

The patient panel is the core asset in a psychiatry practice, more so than in almost any other specialty. Psychiatric patients have long treatment relationships — often years or decades — and they are deeply reluctant to switch providers. A well-maintained panel of 400-600 active patients (seen within the last 6 months) is an extremely sticky revenue base.

Buyers evaluate the panel on several dimensions:

Active patient count. The definition of "active" matters. In psychiatry, a patient seen every 3 months for medication management is active. A patient you haven't seen in 18 months who technically hasn't been discharged is not. Buyers want to see visit frequency data, not just a count of open charts.

Payer mix. Commercial insurance (BCBS, Aetna, UHC) pays $180-$300+ per medication management visit and $150-$250 for therapy sessions. Medicare pays materially less. Medicaid pays even less and comes with administrative burden. A panel that's 60%+ commercial insurance is worth meaningfully more than one that's majority government payers.

Diagnosis complexity. Practices that treat treatment-resistant depression, bipolar disorder, and complex PTSD generate higher revenue per patient (more frequent visits, more complex coding) than practices focused primarily on generalized anxiety and mild depression. Buyers, especially PE-backed platforms, prefer panels with higher-acuity patients because the revenue per encounter is higher.

Medication Management vs. Therapy Split

This is the single biggest driver of practice economics, and therefore valuation. A psychiatrist who spends their day doing 15-minute medication management visits generates dramatically more revenue per hour than one who does 45-minute therapy sessions.

The math is stark. At $250 per med management visit, a psychiatrist seeing four patients per hour generates $1,000/hour. At $200 per therapy session seeing one patient per hour, the same psychiatrist generates $200/hour. Even accounting for the lower overhead of therapy-heavy practices, the EBITDA per provider hour is 2-3x higher for med management.

Buyers strongly prefer practices weighted toward medication management — ideally 70%+ of encounters. The reason isn't just revenue. Therapy is provider-dependent and hard to scale. Medication management can be supported by nurse practitioners and physician assistants under collaborative agreements, which creates leverage and scalability.

A practice doing 80% med management with two NPs working under the psychiatrist's supervision is worth considerably more than a solo psychiatrist doing 60% therapy. The first practice has built a scalable model; the second is selling their personal time.

The Telehealth Factor

Telehealth has transformed psychiatry economics more than almost any other specialty. Pre-2020, psychiatry practices were bound by geography and office capacity. Now, a practice can see patients statewide (or across multiple states with proper licensure) from a home office.

For valuation purposes, telehealth percentage matters in several ways:

High telehealth (60%+) reduces overhead dramatically. A psychiatry practice that's 80% telehealth needs minimal office space — maybe a small suite for in-person evaluations and controlled substance patients. Rent drops from $5-10K/month to $1-2K/month. That savings falls straight to the bottom line and directly increases EBITDA.

Telehealth expands the addressable patient population. A practice in a rural area or a state with acute provider shortages can draw patients from across the state. Buyers see this as growth potential — the panel can be expanded without adding physical infrastructure.

But reimbursement risk exists. Telehealth parity laws vary by state, and there's ongoing regulatory uncertainty about whether current reimbursement rates for telehealth visits will persist. Buyers discount practices that are 90%+ telehealth by 5-10% to account for this regulatory risk. The sweet spot is 50-70% telehealth — enough to capture the margin benefit without full exposure to policy changes.

The Provider Shortage Premium

There are roughly 30,000 practicing psychiatrists in the United States serving a population where approximately 1 in 5 adults has a mental health condition. The average wait time for a new psychiatric appointment is 6-8 weeks in most markets and 3-6 months in underserved areas. This isn't getting better — the workforce pipeline can't keep up with demand growth.

For sellers, this shortage is your most powerful valuation lever. Buyers — especially PE-backed platforms building multi-state behavioral health networks — will pay a premium to acquire an established practice with credentialed providers rather than recruit from scratch. Recruiting a psychiatrist from the open market takes 6-12 months and costs $30-50K in recruiting fees alone, with no guarantee of patient panel or insurance credentialing.

Practices in high-demand markets (Florida, Texas, the rural Midwest) command an additional 1-2x EBITDA premium over practices in provider-saturated markets like Manhattan or San Francisco.

What Drives Psychiatry Practice Value Down

Solo provider dependency. This is the number one issue in psychiatry practice sales. If you are the only prescriber and you leave, those patients need to find a new psychiatrist — and they may not be able to, given wait times. Buyers know that 20-40% of patients will fall off during a transition. The mitigation is bringing on at least one additional prescriber (NP or PA) 12-18 months before selling.

Controlled substance concentration. Practices where a high percentage of patients are on Schedule II controlled substances (stimulants, benzodiazepines) carry regulatory risk that buyers price in. DEA scrutiny, state prescription monitoring programs, and potential liability concerns all factor into the discount. This doesn't make the practice unsellable, but expect 10-15% lower multiples compared to a practice with a more typical prescribing profile.

Outdated EHR and poor documentation. Psychiatry practices that still use paper charts or a decade-old EHR system face a costly migration. More importantly, poor documentation creates compliance risk that sophisticated buyers won't tolerate. If your notes don't support your billing codes, that's a ticking time bomb in a post-acquisition audit.

Maximizing Your Practice Value

If you're planning to sell in the next 2-3 years, the highest-ROI moves are:

Add a prescriber. A psychiatric NP or PA working under your supervision immediately reduces owner dependency, increases capacity, and proves the practice model is scalable. The cost is $120-180K/year in compensation, but the valuation impact can be $300K-$500K+.

Shift toward medication management. If you're doing significant therapy, consider transitioning therapy patients to licensed therapists (LCSWs, LPCs) either in-house or by referral, and focusing your clinical time on med management. This immediately improves revenue per provider hour.

Optimize your telehealth infrastructure. Get credentialed in adjacent states, invest in a HIPAA-compliant platform, and build your telehealth patient base. This demonstrates to buyers that the practice can grow without proportional overhead increases.

Clean up your financials. Psychiatry practices are notorious for running personal expenses through the business — CME travel, professional memberships, home office deductions. Three years of clean, CPA-reviewed financials with clear add-backs makes due diligence smooth and signals a professional operation.

The Bottom Line

Psychiatry practice valuations are at historic highs, driven by an unprecedented demand-supply imbalance and aggressive PE consolidation. If you're sitting on a well-run practice with a solid patient panel and efficient operations, the market is in your favor. But the difference between a 4x and an 8x multiple is preparation, practice structure, and understanding what buyers are actually paying for. Don't leave that value on the table.